ABOUT US

UCL is one of the U.K.’s premier research and teaching Universities (http://www.ucl.ac.uk), ranked within the top 15 global universities, and has one of the largest Biomedical Faculties in Europe. University College Hospital (UCH) is a new state-of-the-art hospital in central London (http://www.uclh.nhs.uk/), with access to all types of imaging, including MRI-PET and other functional imaging, and molecular pathological services. In 2012, the new £110 million UCH Macmillan Cancer Centre opened opposite the UCL Cancer Institute, the hub for cancer research and translation research. This is the UK’s most advanced out-patient cancer care facility.
The UCL Cancer Institute has a total grant income over £100 million, houses over 350 scientists, and includes many clinician scientists among its 61 Group leaders. The Institute is an internationally recognised centre for cancer research, housing state-of-the-art core facilities, including next generation sequencing, bioinformatics, proteomics, single-cell genomics, FACS, confocal microscopy and quantitative and digital PCR. UCL is an Experimental Cancer Medicine Centre and a Cancer Research UK Major Cancer Centre. UCL is also a key partner in an £14m award CRUK to develop a cancer biotherapeutics research hub (https://www.colcc.ac.uk/). UCL is a member of the CRUK International Alliance for the Early Detection of Cancer (ACED, https://www.ucl.ac.uk/cancer/research/centres-and-networks/international-alliance-cancer-early-detection).

ABOUT YOU

The successful candidate will have:
PhD, or evidence of an equivalent level of attainment in research publications
Experience of and commitment to multidisciplinary working and of teaching at undergraduate and postgraduate levels
Leadership skills and the ability to take forward service developments
Applicant seeking appointment at professorial level will be expected to evidence an outstanding international research profile with track record of extensive publications in high quality peer-reviewed scientific journals and invited conference contributions

The appointee will run an independent Immuno-Oncology group at the UCL Cancer Institute aiming to be at the forefront of immuno-therapy research and inline the cancer priority areas set by the NIHR University College London Hospitals Biomedical Research Centre (Cancer | UCLH Biomedical Research Centre).